GEND - ETF AI Analysis
Top Page
Genter Capital Dividend Income ETF (GEND)
GEND, the Genter Capital Dividend Income ETF, earns a solid overall rating driven by strong, diversified holdings like Merck and Accenture, which combine robust financial performance, attractive valuations, and positive growth prospects. Energy names such as Devon Energy and Chevron add upside potential and income, while weaker positions like Microchip and CVS, which face profitability, valuation, and technical challenges, modestly weigh on the fund. The main risk factor is its meaningful exposure to sectors with leverage and cash flow pressures (such as energy and healthcare), which could increase volatility if market or macroeconomic conditions worsen.
GEND vs. SPDR S&P 500 ETF (SPY)
- AUM
- 6.10M
- Region
- North America
- Expense Ratio
- 0.38%
- Beta
- 0.44
- Issuer
- Genter Capital
- Inception Date
- Jan 13, 2025
- Dividend Yield
- 2.83%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
GEND Summary
Genter Capital Dividend Income ETF (GEND) is a U.S.-focused fund that aims to provide steady income by investing in companies that pay high and consistent dividends, rather than tracking a specific index. It spreads money across many sectors like health care, financials, energy, and technology. Well-known holdings include Accenture, Chevron, CVS Health, Merck, and JPMorgan Chase. Someone might invest in GEND to add regular dividend income and diversification to their portfolio. A key risk is that stock prices and dividend payments can go up or down with the overall market and the U.S. economy.
How much will it cost me?
GEND has an annual expense ratio of 0.38%, which means you’ll pay about $3.80 per year for every $1,000 invested. This cost is a bit higher than the average low-cost index ETF because GEND is actively managed, with professionals selecting dividend-focused stocks rather than simply tracking a broad market index.
What would affect this ETF?
Because GEND focuses on U.S. companies with strong dividend payments across sectors like health care, financials, and energy, it can benefit if the economy stays steady, corporate profits grow, and demand for income-focused investments remains high, especially from holdings such as Chevron, JPMorgan, and Merck. On the other hand, rising interest rates, pressure on banks or energy companies, tighter regulations on tobacco or utilities, or a U.S. economic slowdown could hurt company earnings and lead to dividend cuts, which would weigh on the ETF’s future returns.
GEND Top 10 Holdings
GEND leans heavily on U.S. dividend stalwarts, with health care, financials, and energy setting the tone. Merck has been a steady engine of gains, helping anchor the fund, while Chevron and Devon Energy add some fuel with rising energy exposure. JPMorgan and Northern Trust are more mixed, occasionally losing steam as markets reassess banks. On the weaker side, CVS and Enbridge have been lagging, acting as a drag on recent results. Overall, it’s a U.S.-centric, income-focused mix where a few big names do much of the heavy lifting.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 ACN | Accenture | 5.39% | $334.74K | $146.12B | -0.21% | 79Outperform |
 CVX | Chevron | 4.23% | $262.24K | $457.31B | 49.23% | 71Outperform |
 DVN | Devon Energy | 4.12% | $255.70K | $56.29B | 59.66% | 79Outperform |
 NTRS | Northern | 4.21% | $260.94K | $31.64B | 35.88% | 78Outperform |
 MO | Altria Group | 4.13% | $256.19K | $128.15B | 23.85% | 64Neutral |
 CVS | CVS Health | 3.68% | $228.35K | $115.53B | 12.07% | 64Neutral |
 JPM | JPMorgan Chase | 3.74% | $232.26K | $913.30B | 12.46% | 72Outperform |
 MRK | Merck & Company | 3.65% | $226.67K | $361.02B | 69.01% | 80Outperform |
 MCHP | Microchip | 3.74% | $231.92K | $44.05B | 29.71% | 54Neutral |
 ENB | Enbridge | ― | ― | ― | ― | 69Neutral |
GEND Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GEND, the sentiment is Positive. The current price of 13.75 is above the 20-day moving average (MA) of 13.23, above the 50-day MA of 13.21, and above the 200-day MA of 12.67, indicating a bullish trend. The MACD of 0.15 indicates Negative momentum. The RSI at 73.24 is Negative, neither overbought nor oversold. The STOCH value of 76.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GEND.
GEND Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| GEND | $13.75 | $14.50(5.42% Upside) | $6.10M | 0.38% | 70Outperform |
 PAYR | $56.54 | $60.55(7.10% Upside) | $89.52M | 0.40% | 66Neutral |
 HQDG | $25.74 | $31.46(22.24% Upside) | $76.05M | 0.50% | 73Outperform |
 FDIV | $28.09 | $31.76(13.04% Upside) | $55.31M | 0.35% | 70Neutral |
 DIVY | $31.28 | $34.08(8.96% Upside) | $29.48M | 0.45% | 69Neutral |
 VUS | $30.11 | $36.59(21.53% Upside) | $17.26M | 0.25% | 71Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GEND | Genter Capital Dividend Income ETF | 13.75 | 2.95 | 27.26% | |
| PAYR | Federated Hermes Enhanced Income ETF | 56.54 | 11.28 | 24.92% | |
| HQDG | Raub Brock Dividend Growth ETF | 25.74 | 0.74 | 2.98% | |
| FDIV | MarketDesk Focused U.S. Dividend ETF | 28.09 | 2.63 | 10.31% | |
| DIVY | Sound Equity Income ETF | 31.28 | 6.51 | 26.29% | |
| VUS | Virtus US Dividend ETF | 30.11 | 5.62 | 22.97% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.